6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylca rboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an antiinflammatory agent

Details for Australian Patent Application No. 2001275760 (hide)

Owner Glaxo Group Limited

Inventors Nice, Rosalyn Kay; Coote, Steven John; Biggadike, Keith

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2001275760

PCT Pub. Number WO02/12265

Priority 0108800 07.04.01 GB; 0019172 05.08.00 GB

Filing date 3 August 2001

Wipo publication date 18 February 2002

Acceptance publication date 17 March 2005

International Classifications

C07J 031/00 Normal steroids, i.e. cyclopenta[a]hydrophenanthrenes, containing sulfur

A61P 011/08 Drugs for disorders of the respiratory system

A61P 011/06 Drugs for disorders of the respiratory system

A61P 005/44 Drugs for disorders of the endocrine system

A61K 031/58 - containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin

C07J 017/00 Normal steroids containing carbon, hydrogen, halogen, or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta[a]hydrophenanthrene skeleton

Event Publications

17 March 2005 Application Accepted

  Published as AU-B-2001275760

14 July 2005 Standard Patent Sealed

29 May 2008 Extension of Term of Standard Patents

  Glaxo Group Limited The earliest first regulatory approval date provided by the patentee 14 Feb 2008 For the goods AVAMYS fluticasone furoate

22 January 2009 Extension of Term of Standard Patents

  Glaxo Group Limited The earliest first regulatory approval date provided by the patentee 14 Feb 2008 For the goods AVAMYS fluticasone furoate Address for service in Australia: Phillips Ormonde Fitzpatrick Level 22 367 Collins Street Melbourne VIC 3000

11 June 2009 Extension granted

  Glaxo Group Limited The earliest first regulatory approval date provided by the patentee 14 Feb 2008 For the goods AVAMYS fluticasone furoate Extension of Term of patent pursuant to Section 77 expires on 03 Aug 2021

6 August 2009 Extension granted

  Glaxo Group Limited The earliest first regulatory approval date provided by the patentee 14 Feb 2008 For the goods AVAMYS fluticasone furoate Extension of Term of patent pursuant to Section 77 expires on 14 Feb 2023 Applications opposed The following application(s) for Extension of Term have been opposed under Section 75.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001275761

2001275759